戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 us on lymphangioleiomyomatosis and pulmonary Langerhans cell histiocytosis.
2  recurrent and systemic viral infections and Langerhans cell histiocytosis.
3 those of histiocytic human diseases, such as Langerhans cell histiocytosis.
4 ytic conditions, Erdheim-Chester disease and Langerhans cell histiocytosis.
5          Rosai-Dorfman disease is a rare non-Langerhans cell histiocytosis.
6 lymphomas, neuroblastoma, some sarcomas, and Langerhans cell histiocytosis.
7 ues for the routine staging and diagnosis of Langerhans cell histiocytosis.
8  or (event-free) survival in 156 adults with Langerhans cell histiocytosis.
9 iterans organizing pneumonia), and pulmonary Langerhans' cell histiocytosis.
10 ng cancer and in Erdheim-Chester disease and Langerhans'-cell histiocytosis.
11 , xanthogranuloma 7, mixed histiocytosis 11, Langerhans cell histiocytosis 15, and other 2) were exam
12 thma and periocular xanthogranuloma (22%), 7 Langerhans cell histiocytosis (19%), 5 Rosai-Dorfman dis
13                      Included among them are Langerhans cell histiocytosis and hemophagocytic lymphoh
14 y not be associated with tuberous sclerosis, Langerhans cell histiocytosis, and lymphocytic interstit
15 hough lymphangioleiomyomatosis and pulmonary Langerhans cell histiocytosis are perhaps more frequentl
16 umours, gliomas, cysts of Rathke's pouch and Langerhans cell histiocytosis, as well as with genetic n
17  In this study we have developed a model for Langerhans cell histiocytosis comprising a CD1a-positive
18 most common histiocytic disorders, including Langerhans cell histiocytosis, Erdheim-Chester disease,
19 s advantages in the prognosis and staging of Langerhans cell histiocytosis, in a human setting.
20 tential for the future radioimmunotherapy of Langerhans cell histiocytosis is also discussed.
21                                              Langerhans cell histiocytosis is characterized by the ab
22                                    Pulmonary Langerhans'-cell histiocytosis is an uncommon interstiti
23        The survival of adults with pulmonary Langerhans'-cell histiocytosis is shorter than that in t
24 ations have been observed in 57% of cases of Langerhans cell histiocytosis (LCH) and 54% of cases of
25  novel somatic ARAF mutation in a child with Langerhans cell histiocytosis (LCH) and demonstrate that
26                                              Langerhans cell histiocytosis (LCH) and Erdheim-Chester
27 enesis of 2 of the most common histiocytoses-Langerhans cell histiocytosis (LCH) and Erdheim-Chester
28                                              Langerhans cell histiocytosis (LCH) and Erdheim-Chester
29  have been observed in half of patients with Langerhans cell histiocytosis (LCH) and in 50% to 100% o
30  heterogeneous diseases that mostly comprise Langerhans cell histiocytosis (LCH) and non-LCH.
31                                              Langerhans cell histiocytosis (LCH) and the non-LCH neop
32                Two girls were diagnosed with Langerhans cell histiocytosis (LCH) at the age of 16 and
33                                              Langerhans cell histiocytosis (LCH) combines in one noso
34                                              Langerhans cell histiocytosis (LCH) has a broad spectrum
35 nase (ERK) signaling pathway is activated in Langerhans cell histiocytosis (LCH) histiocytes, but onl
36 atients with refractory, risk-organ-positive Langerhans cell histiocytosis (LCH) in 2005.
37         There is little data on treatment of Langerhans cell histiocytosis (LCH) in adults.
38                                              Langerhans cell histiocytosis (LCH) is a clinically and
39                                              Langerhans cell histiocytosis (LCH) is a clonal disorder
40                                              Langerhans cell histiocytosis (LCH) is a clonal hematopo
41                                              Langerhans cell histiocytosis (LCH) is a disorder charac
42                                              Langerhans cell histiocytosis (LCH) is a myeloid neoplas
43                                              Langerhans cell histiocytosis (LCH) is a myeloid neoplas
44                                              Langerhans cell histiocytosis (LCH) is a myeloproliferat
45                                              Langerhans cell histiocytosis (LCH) is a potentially fat
46                                              Langerhans cell histiocytosis (LCH) is a rare disease af
47                                              Langerhans cell histiocytosis (LCH) is a rare disease ch
48                                              Langerhans cell histiocytosis (LCH) is a rare disease wi
49                                              Langerhans cell histiocytosis (LCH) is a rare histiocyti
50                                              Langerhans cell histiocytosis (LCH) is an enigmatic dise
51                                              Langerhans cell histiocytosis (LCH) is an inflammatory m
52                                              Langerhans cell histiocytosis (LCH) is an inflammatory m
53                                              Langerhans cell histiocytosis (LCH) is an inflammatory m
54                                              Langerhans cell histiocytosis (LCH) is an inflammatory n
55                                              Langerhans cell histiocytosis (LCH) is caused by clonal
56                                              Langerhans cell histiocytosis (LCH) is characterized by
57                                              Langerhans cell histiocytosis (LCH) represents a clonal
58 nation with terminal phenotype: for example, Langerhans cell histiocytosis (LCH) shares CD207(+) anti
59 0E) mutation-positive, refractory, childhood Langerhans cell histiocytosis (LCH) was evaluated.
60 of two humans from skeletal collections with Langerhans Cell Histiocytosis (LCH), a benign osteolytic
61 , desquamative interstitial pneumonia (DIP), Langerhans cell histiocytosis (LCH), and acute eosinophi
62                                           In Langerhans cell histiocytosis (LCH), pathologic Langerha
63                                              Langerhans cell histiocytosis (LCH), previously known as
64                                           In Langerhans cell histiocytosis (LCH), the proliferating c
65 ing data to date on a group of patients with Langerhans cell histiocytosis (LCH), which historically
66                                              Langerhans cell histiocytosis (LCH)-III tested risk-adju
67         BRAF mutations have been observed in Langerhans cell histiocytosis (LCH).
68  hypothalamopituitary axis, is documented in Langerhans cell histiocytosis (LCH).
69 of the life-threatening risk organs (ROs) in Langerhans cell histiocytosis (LCH).
70  Thirty-two patients were identified: 7 with Langerhans cell histiocytosis (LCH); 15 with Erdheim-Che
71          An analysis of patients with proven Langerhans' cell histiocytosis (LCH) was undertaken with
72 gree of organ involvement at presentation of Langerhans' cell histiocytosis (LCH) with subsequent dis
73                                              Langerhans-cell histiocytosis (LCH) results from the acc
74                                             "Langerhans cell histiocytosis" (LCH) describes a spectru
75 mon in patients who received transplants for Langerhans cell histiocytosis relative to other indicati
76 9 patients with ECD and ECD overlapping with Langerhans cell histiocytosis (so-called mixed histiocyt
77  Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis that most commonly affects
78 n the cohort with Erdheim-Chester disease or Langerhans'-cell histiocytosis, the response rate was 43
79 with histopathologically confirmed pulmonary Langerhans'-cell histiocytosis to ascertain their vital
80  Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis, to whose pathogenesis neo
81 pendent of these risk factors, patients with Langerhans cell histiocytosis were at significantly incr
82 th survival after the diagnosis of pulmonary Langerhans'-cell histiocytosis were analyzed with the Co
83 d eruptive histiocytosis (GEH) is a rare non-Langerhans cell histiocytosis with a benign, self-healin